Navigation Links
GeoVax Successful HIV/AIDS Vaccine Trial Data Presented at AIDS Vaccine 2007 Conference
Date:9/12/2007

p>

cell) and antibody responses.

-- More volunteers had antibody responses to the full dose than to the

1/10th dose vaccine, whereas response rates for T cells were similar

for the 1/10th and full dose.

-- 2nd MVA vaccination positively increased the number of CD8 T cell

responders and antibody responders.

-- Excellent results led to authorization to start two new trials with

GeoVax HIV/AIDS vaccines which began in June 2007.

These human trials, utilizing GeoVax's HIV/AIDS vaccines, are conducted by the HIV Vaccine Trials Network (HVTN) based in Seattle, Washington. The HVTN, funded and supported by the National Institutes of Health (NIH), is the largest worldwide clinical trials program devoted to the development and testing of HIV/AIDS vaccines. Preclinical work enabling development of the clinical evaluation of GeoVax's DNA and MVA vaccines was also funded and

supported by the NIH National Institute of Allergy and Infectious Diseases (NIAID).

About GeoVax Labs, Inc. (http://www.geovax.com)

GeoVax Inc. is an Atlanta, Georgia USA biotechnology company, established to develop, manufacture, license and commercialize human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents. GeoVax's vaccine technology is protected by 20 issued and filed patent applications.

GeoVax's DNA and Recombinant MVA HIV/AIDS vaccines:

-- Uses DNA for priming the vaccine responses and recombinant MVA to boost

the vaccine response (DNA/MVA vaccine)

-- Protected 22 of 23 (96%) non-human primates for over 3-1/2 years post-

infection with an AIDS causing virus - 5 of 6 non-vaccinated controls

died of AIDS within the 1st year of infection. These trials used a

prototype SIV/HIV vaccine for the HIV vaccine that is being advanced in

human trials

-- Are manufac
'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
2. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
3. Modigene Announces Successful Completion of Pharmacokinetic & Pharmacodynamic Pre-Clinical Experiments for Proprietary Long-Acting Human Growth Hormone, Long-acting Interferon Beta and Long-acting Erythropoietin
4. Second Successful Quigley QR-443 Study Suggests Method of Action Relevant to Broad Range of Chronic Inflammatory Diseases - Human Study to Follow -
5. Javelin Pharmaceuticals Announces Successful Pivotal Phase 3 Trial Data
6. ChemGenex Reports Successful Personalized Dosing of Quinamed at ASCO
7. ChemGenex Reports Successful Personalized Dosing of Quinamed at ASCO
8. BioLineRx Presents Data From Successful Phase I Trial for BL-1020 in Schizophrenia at American Psychiatric Association Conference
9. Sosei Announces Successful Completion of AD 923 Pharmacokinetic Study in the USA
10. Pegasys Study Authors Conclude that Patients Successfully Treated for Hepatitis C Can be Considered Cured
11. SkyePharma and Sciele Pharma Announce Successful Completion of New Sular Formulation Clinical Trial Programme
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2015)... and INDIANAPOLIS , April 28, 2015 /PRNewswire/ ... procedure and receive a heart stent are prescribed an oral ... attack, a blood clot in their heart stent (stent thrombosis), ... Poll found that 52 percent of 275 ACS patients who ... the way they take their prescribed OAP therapy, even though ...
(Date:4/28/2015)... We are living a connected life in a ... and very soon we will be able to connect our ... life market has been valued by Frost & Sullivan at ... drive and manage this change to stay ahead of the ... Highlights of the congress include a groundbreaking keynote address showcasing ...
(Date:4/27/2015)... April 27, 2015 A  study published today ... and presented at the annual Pediatric Academic Societies ... of rapid whole-genome sequencing in neonatal and pediatric intensive ... STAT-Seq test helped diagnose a genetic disease in more ... compared to just nine percent with standard genetic tests. ...
Breaking Medicine Technology:Survey Finds Half of Heart Stent Patients Don't Take Their Oral Antiplatelet Medication As Prescribed 2Survey Finds Half of Heart Stent Patients Don't Take Their Oral Antiplatelet Medication As Prescribed 3Survey Finds Half of Heart Stent Patients Don't Take Their Oral Antiplatelet Medication As Prescribed 4Survey Finds Half of Heart Stent Patients Don't Take Their Oral Antiplatelet Medication As Prescribed 5Survey Finds Half of Heart Stent Patients Don't Take Their Oral Antiplatelet Medication As Prescribed 6Survey Finds Half of Heart Stent Patients Don't Take Their Oral Antiplatelet Medication As Prescribed 7Survey Finds Half of Heart Stent Patients Don't Take Their Oral Antiplatelet Medication As Prescribed 8Survey Finds Half of Heart Stent Patients Don't Take Their Oral Antiplatelet Medication As Prescribed 9Frost & Sullivan's GIL 2015 Unveils the $700 Billion Connected Life Market 2Frost & Sullivan's GIL 2015 Unveils the $700 Billion Connected Life Market 3Study Demonstrates Potential Of Rapid Whole-Genome Sequencing In Critically Ill Infants 2Study Demonstrates Potential Of Rapid Whole-Genome Sequencing In Critically Ill Infants 3
... 2011 Merz Pharmaceuticals today announced the launch of ... their treatment with Xeomin® (incobotulinumtoxinA). XEOMIN is a botulinum ... approved by the U.S. Food and Drug Administration (FDA) ... decrease the severity of abnormal head position and neck ...
... HILLS, Ill., March 8, 2011 Genus Oncology, LLC, a ... cancer, announced it has received an Orphan Drug Designation from ... 1 (MUC1) targeting peptide, GO-203-2c, for the treatment of pancreatic ... the US Orphan Drug Act, is for a product that ...
Cached Medicine Technology:Merz Pharmaceuticals Introduces Comprehensive Programs to Provide Patients With Financial Assistance for Xeomin® (incobotulinumtoxinA) 2Merz Pharmaceuticals Introduces Comprehensive Programs to Provide Patients With Financial Assistance for Xeomin® (incobotulinumtoxinA) 3Merz Pharmaceuticals Introduces Comprehensive Programs to Provide Patients With Financial Assistance for Xeomin® (incobotulinumtoxinA) 4Merz Pharmaceuticals Introduces Comprehensive Programs to Provide Patients With Financial Assistance for Xeomin® (incobotulinumtoxinA) 5Merz Pharmaceuticals Introduces Comprehensive Programs to Provide Patients With Financial Assistance for Xeomin® (incobotulinumtoxinA) 6Genus Oncology, LLC Announces Orphan Drug Status for GO-203-2c for Treatment of Pancreatic Cancer 2
(Date:4/28/2015)... 2015 The PracticeMatch Career Fair ... 8:00 pm at the Sheraton Colonial Boston North Hotel, 1 ... and groups with career opportunities will be attending from across ... free hors d’oeuvres and raffle prize drawings. , Leslie Thompson, ... is an ideal location to hold a career fair. In ...
(Date:4/28/2015)... April 28, 2015 The Awareness Counselor team ... common topic of judging. According to Awareness Counselor, there are ... when directed outward, and to an individual who self-judges. This ... clients as a class or one one one talk. , ... of Awareness Counselor, is that every being on earth is ...
(Date:4/28/2015)... Aliso Viejo, CA (PRWEB) April 28, 2015 ... created for use in Final Cut Pro X ... attention to specific areas on-screen with classic buttons, animated ... Annotate is the perfect compliment to vlogs, video series, ... Cut Pro X 10.2 or newer. ProTube Annotate ...
(Date:4/28/2015)... PREVENT Life Safety, Inc., America’s premier provider ... their Southern California offices from Orange, California to Rancho ... I (letter I), Rancho Cucamonga, CA, 91730, is effective ... the significant growth the company has realized in the ... to provide superior life safety services, including fire damper ...
(Date:4/27/2015)... 2015 Medical Device Design Control , ... Ombu Enterprises**, June 16-17, 2015 – Chicago, IL , ... to a facility today, would the design control system ... is "maybe" or "no" … then very likely there ... a solution. , Take this important step. Enroll ...
Breaking Medicine News(10 mins):Health News:PracticeMatch to Host Physician Career Fair at Sheraton Colonial Boston North Hotel on May 6, 2015 2Health News:PracticeMatch to Host Physician Career Fair at Sheraton Colonial Boston North Hotel on May 6, 2015 3Health News:What Happens When We Judge Ourselves and Others? – A New Concept Introduced 2Health News:What Happens When We Judge Ourselves and Others? – A New Concept Introduced 3Health News:FCPX plugin developer Pixel Film Studios releases Protube Annotate plugin for Final Cut Pro X. 2Health News:PREVENT Life Safety Moves to New Office in Rancho Cucamonga 2Health News:FDAnews Announces: Medical Device Design Control: Implementing an Approach That Works, June 16-17, Chicago, IL 2Health News:FDAnews Announces: Medical Device Design Control: Implementing an Approach That Works, June 16-17, Chicago, IL 3Health News:FDAnews Announces: Medical Device Design Control: Implementing an Approach That Works, June 16-17, Chicago, IL 4
... smokers twice as likely to have strokes, they are almost ... to a study presented today at the Canadian Stroke Congress. ... stroke patients (264 smokers and 718 non-smokers) at an Ottawa ... who smoked was 58, compared to age 67 for non-smokers. ...
... in South Africa and Brazil become happier as they age. ... a developing country can significantly improve the wellbeing of its ... older people in South Africa and Brazil improved between 2002 ... enlightened social policies, according to a study from the New ...
... By Amanda Gardner HealthDay Reporter , FRIDAY, ... United States, which reached a record high last year, are ... So far this year, some 200 drug shortages have ... Jensen, associate director of the Drug Shortage Program within the ...
... using a 320 detector row CT scanner found that a ... sufficient enhancement in more than 96% of coronary segments," said ... and one of the authors of the study. ... equal to 80 milliliters of iopamidol," he said. The ...
... such as depression, obsessive-compulsive disorder or anxiety states ... of the neurotransmitter serotonin. Neurotransmitters are compounds that ... endings and activate the firing of neighboring neurons. ... transmission of nerve impulses. The serotonin transporter (SERT) ...
... women experience peer pressure to share sexual images via the ... Melbourne study has found. ,Sexting, is the practice of ... The study is one of the first academic investigations ... findings were presented to the 2011 Australasian Sexual Health Conference ...
Cached Medicine News:Health News:Smoking causes stroke to occur 2Health News:Older people are happier in Brazil and South Africa 2Health News:Drug Shortages Even Worse This Year: FDA 2Health News:Combating mood disorders 2Health News:'Sexting' driven by peer pressure 2
MP-250N and 300N is a new style power supply. It is a versatile microprocessor power supply for horizontal or vertical gel electrophoresis. The unit is programmable and offers constant voltage and co...
... ZOOM® Dual Power is a microprocessor-controlled ... both high voltage/low current and high ... voltage/low current section is ideal for ... DNA sequencing applications. The low voltage/high ...
... Power Supply is designed specifically ... extensive programming capabilities including eight ... for you to set to ... intuitive PowerEase interface is faster ...
PS2A200 Power supply is a high current power supply ideal for all types of electrophoresis blotting and short electrophoresis runs....
Medicine Products: